Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:24:00 EDT Tue 09 Jun 2026
Enter Symbol
or Name
USA
CA



Z:JNJ - JOHNSON & JOHNSON - https://www.jnj.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
JNJ - Z5.0230.00·235.000.3232.16-0.595-0.37,559.51,740,818114,731232.77  234.95  230.5601251.705  149.0419:59:3308:0015 min RT 2¢

Recent Trades - Last 10 of 114731
Time ETExPriceChangeVolume
19:59:33Z232.00-0.775
19:58:01Z231.26-1.511
19:56:37Z232.900.131
19:56:16Z232.850.081
19:54:40Z232.20-0.5750
19:54:35Z230.6087-2.16131
19:52:37Z231.74-1.0336
19:52:37Z231.74-1.0325
19:51:06Z230.8555-1.914525
19:39:17Z232.50-0.2748

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-06-08 08:00U:JNJNews ReleaseJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
2026-06-03 00:04U:JNJNews ReleaseJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study
2026-06-03 00:03U:JNJNews ReleaseJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjogren's disease
2026-05-31 08:29U:JNJNews ReleaseRYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
2026-05-31 08:15U:JNJNews ReleaseJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA(TM) (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
2026-05-29 14:00U:JNJNews ReleaseRYBREVANT(TM) (amivantamab-vmjw) plus LAZCLUZE(TM) (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
2026-05-29 08:17U:JNJNews ReleaseNew TECVAYLI(TM) (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
2026-05-28 19:10U:JNJNews ReleaseFDA approves label expansion, cementing TREMFYA(TM) as the only IL-23 inhibitor proven to help stop further joint damage
2026-05-27 16:22U:JNJNews ReleaseJohnson & Johnson to Host Investor Conference Call on Second-Quarter Results
2026-05-14 16:01U:JNJNews ReleaseGroundbreaking global survey captures the significant patient burden experienced with current standard-of-care bladder cancer treatments, underscoring urgency for continued innovation
2026-05-13 08:30U:JNJNews ReleaseCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
2026-05-12 07:45U:JNJNews ReleaseJohnson & Johnson Advances the Standard of Calcium Modification with Global Launch of Shockwave(TM) C2 Aero Coronary IVL Catheter
2026-05-11 16:34U:JNJNews ReleaseJohnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-11 08:00U:JNJNews ReleaseJohnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP
2026-05-07 08:00U:JNJNews ReleaseJohnson & Johnson launches "Generation Fine," a New Movement Encouraging Patients to Expect More from Depression Treatment and Aim for Remission
2026-05-05 08:05U:JNJNews ReleaseJohnson & Johnson study shows TREMFYA(TM) (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
2026-05-05 08:05U:JNJNews ReleaseJohnson & Johnson investigational co-antibody therapy JNJ-4804 shows potential to raise the bar for clinical efficacy in treating refractory inflammatory bowel disease
2026-05-05 07:00U:JNJNews ReleaseJohnson & Johnson Announces Pivotal Clinical Study Results for a New Soft-Tissue Surgical Robotic System
2026-05-04 08:00U:JNJNews ReleaseCAPLYTA(TM) (lumateperone) showed greatest improvement across key efficacy outcomes among adjunctive MDD treatments in new network meta-analysis
2026-04-30 08:02U:JNJNews ReleaseJohnson & Johnson Appoints Ryan Koors as Vice President, Investor Relations